Long-term risk of major coronary artery disease events after thrombotic microangiopathy treated with plasma exchange

No abstract available.

Information

Citation

Jamison HK, Bota SE, Garg AX, Kang Y, McArthur E, Huang SS, Clark WF, Sontrop JM, Eberhart AM. Am J Hematol. 2026; Mar 9 [Epub ahead of print].

View Source

Discover More

Journal Article

16/03/2026

Hydralazine use and risk of vasculitis

Fremont D, Dhaliwal S, Canney M, Akbari A, Hundemer GL, Derebail VK, Sood MM, Massicotte-Azarniouch D. JAMA Netw Open. 2026; 9(3): e261943.

Journal Article

09/03/2026

Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents

Wang TF, Clarke A, Rath M, Yoo S, Fremont D, Wu C, Ravani P, Bossé D, Talarico R, Carrier M, Sood MM. Cancer. 2026; 132(6):e70266.

Journal Article

25/02/2026

Impact of wait-times for atrial fibrillation ablation on cumulative healthcare costs

Qeska D, Qiu F, Manoragavan Mma R, Abdel-Qadir H, Cheung CC, Ko DT, Singh SM, Sud MK, Wijeysundera HC. Heart Rhythm. 2026; S1547-5271(26)00154-2. Epub 2026 Feb 25.

See All

Long-term risk of major coronary artery disease events after thrombotic microangiopathy treated with plasma exchange

Information

Citation

Contributing ICES Scientists

Research Programs

Associated Topics

Associated Sites

Discover More

Hydralazine use and risk of vasculitis

Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents

Impact of wait-times for atrial fibrillation ablation on cumulative healthcare costs